© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - CEO of the Month, Belgium: Jan De Backer, FLUIDDA
Posted 28th October 2015

CEO of the Month, Belgium: Jan De Backer, FLUIDDA

FLUIDDA develop proprietary diagnostics for lung diseases, such as asthma, chronic obstructive pulmonary disease and lung fibrosis.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

CEO of the Month, Belgium: Jan De Backer, FLUIDDA

CEO of the Month – Jan De Backer, FLUIDDA

Image

FLUIDDA develop proprietary diagnostics for lung diseases, such as asthma, chronic obstructive pulmonary disease (COPD) and lung fibrosis. The technology, called Functional Respiratory Imaging or FRI is a combination of high-resolution CT scans and computer methods that simulate the flow in the lungs.

FRI provides an unparalleled insight into how the lungs of specific patients work. Airways, blood vessels and airflow can be visualised and analysed in great detail. In addition, FRI can determine where inhaled drug particles end up in the lungs of patients. FLUIDDA uses FRI to help pharmaceutical companies develop better drugs for lung diseases, faster and cheaper. Additionally the firm also work with individual physicians to help them to select the most appropriate treatment for specific patients, which is unusual as it requires a more costly trial and error approach not usually adopted by other firms in the industry.

Jan started at the company in 2005 and has since helped the firm to differentiate itself from its competitors by becoming active in the R&D phase of development, where their technology can inform pharmaceutical and biotech companies very quickly whether the compound is worthwhile pursuing.

The firm are also involved in the marketing phase where their visualisations of the mode of action of the drug, based on real patient data, is used to show the added value of the drug or device to doctors, insurance companies as well as being active in clinical practice where the company can leverage the knowledge from the clinical trials to assist the doctor in selecting the most optimal treatment for individual patients based on the patient specific characteristics.

Jan explained the firm’s vision and how he ensures that this is upheld by everyone within the firm.
“My role as CEO has evolved over the years. I started the company ten years ago and at that time the emphasis of the company was mainly on the development of the technology. We had to perform our clinical validation trials and ensure the technology became scalable. Gradually my role became more general management with the focus on international expansion (we opened an office in India in 2010 and in the US in 2012) and developing a vision for sustained growth.

“This vision, nowadays, revolves very much around levering modern day technology to improve the efficiency, including the cost/benefit ratio, of many facets of the healthcare system. This includes drug development, treatment optimization in clinical practice and even patient education. We feel that a system where all stakeholders align around the patient interest is a system with the highest probability of success to improve the efficiency of the healthcare system.

“Communication is key to ensure that everyone in the company is aware of our vision and that they do whatever is needed to support it. Despite a very busy travel schedule I try to keep in touch with the teams in the different locations as much as possible. Every month I update the company, including our directors, on the latest developments. This is good opportunity to either welcome people to the team, congratulate the teams on the performance or to caution for potential threats in the foreseeable future. Our people know that if there is an issue they can always bring it my attention and I will do whatever I can to resolve it.”

Being a technology company in the healthcare industry means being exposed to a number of rapidly changing markets, with regulation, technology and health innovation constantly evolving. Jan described the market and how the changes affected FLUIDDA.

“I strongly believe that we are on the verge of a revolution in healthcare. We see important stakeholders such as governments, patient advocacy groups and a new generation of doctors all converge around implementing new technologies to make the system more efficient. This is largely driven by the budgetary constraints due to the exponential increase in the healthcare costs and the additional challenges in healthcare due to the aging population.

“As a company we have invested greatly in being able to translate, often complex, technology into a format fit for the medical world. We do not expect doctors to become technical experts but we rather make our technology as accessible as possible for the physician. We like to harness the power of modern technology such as high-performance computing and big data and convert that into personalised medicine in collaboration with the medical professionals. FLUIDDA aims to do that in a sustainable manner, which should ensure our position as a leading edge technology partner.”

Overall, Jan made it clear that these changes in the industry, now and in the future, would keep the firm at the very height of innovation.

“This is an exciting time for healthcare. There is a high need to change to keep the system affordable. At the same time, the level of implementation of modern technology (cloud services, home monitoring, personalised diagnostics, etc) is relatively low. Companies that manage to implement this type of new technology will have a bright future. Within FLUIDDA we will strive to be one of those companies by continuing to transform excellent science into readyto- use applications for doctors and researchers.”

Company: FLUIDDA

Name: Jan De Backer

Email: [email protected]

Web: www.FLUIDDA.com

Address: Groeningenlei 132,

2550 Kontich, Belgium

Telephone: +32 3 450 87 20

Categories: Leadership


You Might Also Like
Read Full PostRead - Eye Icon
Tangiers Group Acquires Osprey
Finance
08/04/2015Tangiers Group Acquires Osprey

Tangiers Group Acquires Osprey

Read Full PostRead - Eye Icon
Better Capital’s Acquisition of CAV Aerospace
Innovation
01/04/2015Better Capital’s Acquisition of CAV Aerospace

Better Capital's Fund II has committed £40m to CAV Aerospace.

Read Full PostRead - Eye Icon
Nok Nok Labs announces optimised integration with security key pioneer Yubico
Innovation
14/11/2019Nok Nok Labs announces optimised integration with security key pioneer Yubico

Nok Nok Labs, the trusted leader in next-generation consumer authentication has announced optimised integration with Yubico, the leading provider of hardware authentication security keys. The integration provides enterprises worldwide the ability to easily use

Read Full PostRead - Eye Icon
How to build and manage credible partnerships and affiliations in business
Finance
21/02/2018How to build and manage credible partnerships and affiliations in business

The rapid rise of brands and companies partnering with experts and influencers to endorse products or services has been ever-increasing in our social media focused world.

Read Full PostRead - Eye Icon
How to Identify and Prevent a Cyber Attack
Innovation
13/01/2023How to Identify and Prevent a Cyber Attack

Cyber threats and risks are evolving at an increasingly rapid scale. Businesses everywhere are failing to react quickly enough to malicious cyber attacks, and as such, they can suffer irreparable damage to finances, systems, data and reputation.

Read Full PostRead - Eye Icon
Leveraging AI for Fraud Detection and Risk Assessment in the FinTech
News
22/01/2024Leveraging AI for Fraud Detection and Risk Assessment in the FinTech

While ChatGPT become lazy recently, denying to perform basic tasks, and making excuses on why it shouldn’t do, what was required, it is still hard to deny that machine learning models can bring many advantages to any technological solution, and FinTech i

Read Full PostRead - Eye Icon
How a Good Forex Prop Firm Enhances Your Forex Prop Trading
Finance
11/04/2022How a Good Forex Prop Firm Enhances Your Forex Prop Trading

Finding a good forex prop firm is not easy, we will admit that. Rather than telling you what to look for, we will go through what City Traders Imperium’s (CTI) forex prop firm has to offer to make your forex prop trading journey as smooth as possible.

Read Full PostRead - Eye Icon
7 Strategies to Managing Your Business Cash Flow
News
31/05/20227 Strategies to Managing Your Business Cash Flow

As a business owner, you know that cash flow and business capital are critical. If you can’t manage your cash flow effectively, your business will struggle. Read on to learn how to better manage your business cash flow. Make a Budget and Stick to It With

Read Full PostRead - Eye Icon
Running a Professional Options Trading Business from Home
Innovation
21/02/2023Running a Professional Options Trading Business from Home

When you run a professional options trading business, you gain the right to buy or sell assets at a set price prior to a specific date. These days, investors can begin options trading from home. Do it right, and you could end up with healthy profits.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow